Serum Omentin-1 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease

October 4, 2012 updated by: Kocaeli Derince Education and Research Hospital

The Relationship Between Serum Omentin-1 and IL-6 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease

The aim of the study is to evaluate whether a low level of serum omentin-1 is associated with carotid atherosclerosis and mediated by inflammation.

Study Overview

Status

Unknown

Conditions

Detailed Description

Atherosclerotic cardiovascular disease is markedly increased in chronic kidney disease. There are a lot of risk factor, along with conventional risk factors. Serum onemtin-1 is a adipokine and suggested as a new marker for vascular disease.It has some anti-atherogenic properties. Studies investigating serum omentin-1 level have usually conducted in patients with diabetes mellitus.

Study Type

Observational

Enrollment (Anticipated)

85

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
    • Kocaeli
      • Izmit, Kocaeli, Turkey, 41100
        • Recruiting
        • Department of Nephrology, Check-up Clinic,Kocaeli Derince Education and Traning Hospital
        • Contact:
        • Principal Investigator:
          • Erkan SENGUL, MD
        • Sub-Investigator:
          • Gokhan DUYGULU, MD
        • Sub-Investigator:
          • Sevim DINDAR, MD
        • Sub-Investigator:
          • Fatih BUNUL, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Department of Nephrology, Check-up clinic

Description

Inclusion Criteria:

  • between ages of 18 - 65 years old chronic kidney disease of stage 3-4

Exclusion Criteria:

  • Chronic kidney disease of stage 5
  • The history of ischemic cardiovascular disease (myocardial infarction, unstable angina, stroke, peripheral artery disease, or cardiovascular revascularization)
  • Severe heart failure
  • Stage 2 hypertension
  • Diabetes mellitus
  • Corticosteroid therapy
  • Severe hepatic disease
  • Smoking
  • Inflammatory disease
  • Acute infectious disease
  • Malignancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Case Group
Patients with chronic kidney disease of stage 3-4.
Control group
30 healthy subject

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Kocaeli Derince Education and Research Hospital

Investigators

  • Principal Investigator: Erkan SENGUL, MD, Kocaeli Derince Education and Training Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2012

Study Completion (ANTICIPATED)

May 1, 2013

Study Registration Dates

First Submitted

October 3, 2012

First Submitted That Met QC Criteria

October 4, 2012

First Posted (ESTIMATE)

October 5, 2012

Study Record Updates

Last Update Posted (ESTIMATE)

October 5, 2012

Last Update Submitted That Met QC Criteria

October 4, 2012

Last Verified

October 1, 2012

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2012/02

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Atherosclerosis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe